Subscribe To

Price Alert Latest News Economic Calendar News

HROW / Harrow Health's (HROW) CEO Mark L. Baum on Q1 2022 Results - Earnings Call Transcript

Harrow Health's (NASDAQ:HROW ) Q1 2022 Earnings Conference Call May 5, 2022 4:45 PM ET Company Participants Jamie Webb - Director of Communications and Investor Relations Mark Baum - Chief Executive Officer and Chairman of the Board Andrew Boll - Chief Financial Officer Conference Call Participants Destiny Buch - Ladenburg Thalmann Nathan Weinstein - Aegis Capital Sahil Kazmi - B. Riley Securities Operator Good afternoon, and welcome to Harrow Health's Q1 2022 Earnings Conference Call. Read More

Demo Live Account See Partner Details

Content Topics

Harrow

Health

HROW

Mark

Baum

2022

Results

Earnings

Call

Health s

hrow

Transcript

Stock

Posted: May 8 2022, 20:32

Author Name: Seeking Alpha

HROW News

By Seeking Alpha
September 27, 2023

Harrow Health's 5-Year Guidance

Harrow Health has guided to at least $1 billion in revenue by 2027 based on their current portfolio of drugs. The company's deep moat and strong custo

By Seeking Alpha
August 9, 2023

Harrow Health, Inc. (HROW) Q2 2023 Earnings Call Transcript

Harrow Health, Inc. (NASDAQ:HROW ) Q2 2023 Earnings Conference Call August 9, 2023 4:45 PM ET Company Participants Jamie Webb - Director-Communication

By Seeking Alpha
August 1, 2023

Harrow Health And Its Interesting 11.6% 2027 Baby Bond

Harrow Health is an eye care pharmaceuticals company. The common stock has been on fire with expectations of rapidly increasing profits. HROW has 2 ba

By Zacks Investment Research
July 20, 2023

Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength?

Harrow (HROW) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the st

By The Motley Fool
July 19, 2023

Why Shares of Harrow Health Are Jumping Wednesday

Harrow added seven new products through an acquisition. The company said it expects increased revenue year over year in the second quarter.

By Zacks Investment Research
June 23, 2023

Harrow Health (HROW) Flat As Market Sinks: What You Should Know

Harrow Health (HROW) closed at $18.52 in the latest trading session, marking no change from the prior day.

By Seeking Alpha
June 12, 2023

Harrow Health: Mostly Good, Some Bad

Harrow Healthcare is well-positioned to grow in the US Ophthalmology market, with a branded pharma sales strategy that could boost growth and margins.

By The Motley Fool
May 12, 2023

Why Shares of Harrow Health Are Slumping Friday

Harrow had a $6.6 million loss in the first quarter. It just launched its latest therapy, the ocular anesthesia Iheeza.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.